Research Analysts Issue Forecasts for BMY Q1 Earnings
William Blair reduced their Q1 2026 EPS estimates for Bristol-Myers Squibb in a research report issued to clients and ...
Insider trades: JPMorgan, Bristol-Myers Squibb among notable names this week
A weekly summary of insider trading highlighting a few notable buying and selling by investors, directors and executives. The ...
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
Exelixis, Inc. (NASDAQ:EXEL) authorized repurchasing up to an additional $500 million of the company’s common stock before December 31, 2025. Exelixis plans to complete the $500 million stock ...
Hosted on MSN2d
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?
JPMorgan is sticking with Eli Lilly (LLY) as its top biopharma pick for 2025, while also highlighting Gilead Sciences (GILD) ...
Bristol Myers Squibb Names New GC as Legal Chief Retires
Bristol Myers Squibb Co. said Cari Gallman, the company’s executive vice president for corporate affairs, will become its ...
Healio3d
Q&A: ‘Everyone benefits’ from noninvasive, individualized monitoring in pediatric IBD
Noninvasive monitoring methods, such as enterography and ultrasound, are becoming increasingly recognized as essential tools ...
Medscape3d
Diet Changes Show Promise in Early Prostate Cancer
A high omega-3, low omega-6 diet with fish oil led to a significant reduction in a biomarker for prostate cancer progression ...
Cramer's Lightning Round: Deere is a buy
Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...
Targeted Oncology4d
Discussing Lung Cancer NGS Testing and EGFR Treatment Strategies
During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their ...
Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer
Bristol Myers' Opdivo improved overall survival in resectable NSCLC, per final Phase 3 data. The study confirms its benefit when combined with chemotherapy.